期刊
ARTHRITIS RESEARCH & THERAPY
卷 12, 期 -, 页码 -出版社
BMC
DOI: 10.1186/ar2884
关键词
-
类别
资金
- Alliance for Lupus Research
- Swedish Research Council
- Dana Foundation
- Swedish Rheumatism Association
- Gustafsson Foundation
- King Gustaf V 80th Birthday Foundation
- COMBINE
Patients with lupus have a continuous production of IFN alpha and display an increased expression of IFN alpha-regulated genes. The reason for the ongoing IFN alpha synthesis in these patients seems to be an activation of plasmacytoid dendritic cells (pDCs) by immune complexes (ICs), consisting of autoantibodies in combination with DNA-containing or RNA-containing autoantigens. The mechanisms behind the activation of pDCs by such ICs have to some extent been elucidated during the last years. Thus, interferogenic ICs are internalized via the Fc gamma RIIa expressed on pDCs, reach the endosomes and stimulate Toll-like receptor (TLR) 7 or 9, which subsequently leads to IFN alpha gene transcription. Variants of genes involved in both the IFN alpha synthesis and response have been linked to an increased risk to develop lupus. Among these genes are interferon regulatory factor 5 (IRF5), which is involved in TLR signaling, and the signal transducer and activator of transcription 4 (STAT4) that interacts with the type I interferon receptor. Produced IFN alpha may at least partially be responsible for several of the observed alterations in the immune system of lupus patients and contribute to the autoimmune disease process, which will be discussed in the present review. How produced IFN alpha can contribute to some clinical manifestations will briefly be described, as well as the possible consequences of this knowledge in clinical practice for disease monitoring and therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据